V. Chounta

发表

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Sterling Wu, S. Snedecor, N. van de Velde, 2022, BMC Infectious Diseases.

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Sterling Wu, S. Snedecor, N. van de Velde, 2020, BMC Infectious Diseases.

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

S. Swindells, Kimberly Smith, H. Crauwels, 2021, AIDS (London, England).

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV

L. Matza, T. Paulus, K. Deger, 2020, The Patient - Patient-Centered Outcomes Research.

Quantifying people living with HIV who would benefit from an alternative to daily oral therapy: Perspectives from HIV physicians and people living with HIV

J. Noone, G. Nachbaur, L. Finkielsztejn, 2020 .

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study

S. Anderson, T. Ward, D. Becker, 2021, PloS one.

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

P. Cahn, S. Swindells, J. Mrus, 2020, The New England journal of medicine.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

S. Walmsley, M. Murray, Jenny Huang, 2020, AIDS and Behavior.

Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe

G. Nachbaur, B. Akinwunmi, L. Finkielsztejn, 2021, European journal of public health.

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence

S. Kaur, A. de Ruiter, L. Evitt, 2021, HIV medicine.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries

G. Nachbaur, B. Akinwunmi, L. Finkielsztejn, 2021, Sexually Transmitted Infections.

Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.

J. Piercy, G. Tremblay, Y. Punekar, 2018, Value in health regional issues.